A phase II study of perifosine in patients with relapsed/refractory Waldenstrom's macroglobulinaemia.

Trial Profile

A phase II study of perifosine in patients with relapsed/refractory Waldenstrom's macroglobulinaemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Perifosine (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2011 Planned End Date changed from 1 Sep 2011 to 1 Oct 2011, according to ClinicalTrials.gov record.
    • 23 Feb 2010 Planned end date changed from 1 Mar 2009 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 29 Jan 2010 Positive top-line data reported in a Keryx Biopharmaceuticals media release, with results to be published in the February 1, 2010 issue of Clinical Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top